These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33116132)

  • 1. Immune modulatory effects of oncogenic KRAS in cancer.
    Hamarsheh S; Groß O; Brummer T; Zeiser R
    Nat Commun; 2020 Oct; 11(1):5439. PubMed ID: 33116132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the ERβ/HER Oncogenic Network in
    Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications.
    Pereira F; Ferreira A; Reis CA; Sousa MJ; Oliveira MJ; Preto A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159208
    [No Abstract]   [Full Text] [Related]  

  • 5. Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models.
    Chew TW; Liu XJ; Liu L; Spitsbergen JM; Gong Z; Low BC
    Oncogene; 2014 May; 33(21):2717-27. PubMed ID: 23812423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conquering oncogenic KRAS and its bypass mechanisms.
    Hou P; Wang YA
    Theranostics; 2022; 12(13):5691-5709. PubMed ID: 35966590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish.
    Yan C; Huo X; Wang S; Feng Y; Gong Z
    J Hepatol; 2015 Aug; 63(2):420-8. PubMed ID: 25828472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
    Wood K; Hensing T; Malik R; Salgia R
    JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
    Sayed S; Sidorova OA; Hennig A; Augsburg M; Cortés Vesga CP; Abohawya M; Schmitt LT; Sürün D; Stange DE; Mircetic J; Buchholz F
    Cancer Res; 2022 Sep; 82(17):3002-3015. PubMed ID: 35802645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.
    Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G
    Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions.
    Watterson A; Coelho MA
    Cell Commun Signal; 2023 Mar; 21(1):45. PubMed ID: 36864508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance.
    Pelullo M; Nardozza F; Zema S; Quaranta R; Nicoletti C; Besharat ZM; Felli MP; Cerbelli B; d'Amati G; Palermo R; Capalbo C; Talora C; Di Marcotullio L; Giannini G; Checquolo S; Screpanti I; Bellavia D
    Cancer Res; 2019 Nov; 79(21):5575-5586. PubMed ID: 31506332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased tumorigenesis in mice with a Kras point mutation at C118.
    Huang L; Carney J; Cardona DM; Counter CM
    Nat Commun; 2014 Nov; 5():5410. PubMed ID: 25394415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
    Ambrogio C; Barbacid M; Santamaría D
    Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare codons capacitate Kras-driven de novo tumorigenesis.
    Pershing NL; Lampson BL; Belsky JA; Kaltenbrun E; MacAlpine DM; Counter CM
    J Clin Invest; 2015 Jan; 125(1):222-33. PubMed ID: 25437878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.